Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole - PubMed
Clinical Trial
. 2009 May-Jun;27(3 Suppl 54):15-21.
Affiliations
- PMID: 19796556
Clinical Trial
Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole
Y Muro et al. Clin Exp Rheumatol. 2009 May-Jun.
Abstract
Objective: The high frequency of gastroesophageal reflux disease (GERD) as a complication of scleroderma (systemic sclerosis, SSc) calls for treatment with powerful acid suppressants such as proton pump inhibitors (PPI). The present study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc patients, and examine the effectiveness of rabeprazole (RPZ) for treating the symptoms of GERD.
Methods: The Frequency Scale for the Symptoms of GERD (FSSG), a medical questionnaire developed in Japan for evaluating GERD, and the Visual Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, respectively, in 151 SSc subjects. These tools were also used to assess the effect of 8 weeks' treatment with the PPI RPZ (10 mg/day).
Results: Data on age and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ treatment, were available for 84 subjects. The mean FSSG score was 13.9+/-9.7 before treatment, 8.3+/-8.1 after 4 weeks of treatment, and 7.0+/-7.0 after 8 weeks of treatment; the score reduction was significant (p<0.001) indicating the effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores revealed a significant improvement in pain after both 4 and 8 weeks compared with baseline scores. Six subjects experienced adverse effects and five discontinued the analysis during the period.
Conclusion: Administration of RPZ 10 mg/day is effective for the control of the symptoms of GERD associated with SSc. In addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to evaluate the therapeutic effect of drugs.
Similar articles
-
Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y, Umegaki E, Higuchi K, Kusano M, Arakawa T; GERD 4 Study Group. Tominaga K, et al. J Gastroenterol. 2012 Mar;47(3):284-92. doi: 10.1007/s00535-011-0488-5. Epub 2011 Nov 15. J Gastroenterol. 2012. PMID: 22081052 Clinical Trial.
-
Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom Research Group. Furuta T, et al. J Gastroenterol. 2011 Nov;46(11):1273-83. doi: 10.1007/s00535-011-0446-2. Epub 2011 Aug 24. J Gastroenterol. 2011. PMID: 21861141 Clinical Trial.
-
Fujiwara Y, Habu Y, Ashida K, Kusano M, Higuchi K, Arakawa T. Fujiwara Y, et al. Digestion. 2013;88(3):145-52. doi: 10.1159/000354071. Epub 2013 Sep 5. Digestion. 2013. PMID: 24008338 Clinical Trial.
-
Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Lim PW, Goh KL. Lim PW, et al. J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S61-8. doi: 10.1111/j.1440-1746.2004.03592.x. J Gastroenterol Hepatol. 2004. PMID: 15324384 Review.
-
[Questionnaires for GERD, QUEST and F scale].
Kusano M. Kusano M. Nihon Rinsho. 2007 May;65(5):846-51. Nihon Rinsho. 2007. PMID: 17511223 Review. Japanese.
Cited by
-
Hughes M, Allanore Y, Baron M, Del Galdo F, Denton CP, Frech T, Furst DE, Galetti I, Dagna L, Herrick AL, Kuwana M, Matucci-Cerinic P, McMahan ZH, Murray CD, Proudman S, Matucci-Cerinic M. Hughes M, et al. Lancet Rheumatol. 2022 Nov;4(11):e795-e803. doi: 10.1016/S2665-9913(22)00183-7. Epub 2022 Jul 25. Lancet Rheumatol. 2022. PMID: 37936680 Free PMC article.
-
Patient-reported outcome instruments in clinical trials of systemic sclerosis.
Pauling JD, Caetano J, Campochiaro C, De Luca G, Gheorghiu AM, Lazzaroni MG, Khanna D. Pauling JD, et al. J Scleroderma Relat Disord. 2020 Jun;5(2):90-102. doi: 10.1177/2397198319886496. Epub 2019 Nov 25. J Scleroderma Relat Disord. 2020. PMID: 35382020 Free PMC article. Review.
-
Approach to esophageal absent contractility: can we do better?
Mari A, Cohen S, Cohen DL, Khoury T, Baker FA, Abboud W, Savarino EV, Pesce M. Mari A, et al. Ann Gastroenterol. 2024 Mar-Apr;37(2):117-124. doi: 10.20524/aog.2024.0860. Epub 2024 Feb 13. Ann Gastroenterol. 2024. PMID: 38481777 Free PMC article. Review.
-
Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease.
Tabuchi M, Minami H, Akazawa Y, Ashida M, Hara T, Ichinose K, Kitayama M, Hashiguchi K, Matsushima K, Yamaguchi N, Takeshima F, Kondo H, Kawakami A, Nakao K. Tabuchi M, et al. Biomed Rep. 2021 Feb;14(2):25. doi: 10.3892/br.2020.1401. Epub 2020 Dec 17. Biomed Rep. 2021. PMID: 33408859 Free PMC article.
-
Esophageal manifestation in patients with scleroderma.
Voulgaris TA, Karamanolis GP. Voulgaris TA, et al. World J Clin Cases. 2021 Jul 16;9(20):5408-5419. doi: 10.12998/wjcc.v9.i20.5408. World J Clin Cases. 2021. PMID: 34307594 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical